Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
May 15 2019 - 8:05AM
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company focused
on treating inflammatory and fibrotic diseases by targeting the
endocannabinoid system, today announced that Yuval Cohen, Ph.D.,
Chief Executive Officer of Corbus, will present at two upcoming
investor conferences in May.
The following are the details for the
conferences:
Event: Live Fireside Chat at 2019 RBC Capital
Markets Global Healthcare Conference
Date: Tuesday, May 21, 2019
Time: 10:00 a.m. Eastern Time
Location: InterContinental New York Barclay
Hotel, New York, NY
Event: Annual B. Riley FBR Institutional
Investor Conference
Date: Thursday, May 23, 2019
Time: 1:00 p.m. Pacific Time
Location: Beverly Hilton, Beverly Hills, CA
Live audio webcast of both the presentations
will be accessible on the Events page of the Investors section of
the Corbus website, www.corbuspharma.com and will be archived for
90 days following the event. About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of endocannabinoid
system-targeting synthetic drug candidates. The Company's lead
product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug
candidates from more than 600 novel compounds targeting the
endocannabinoid system. The pipeline includes CRB-4001, a 2nd
generation, peripherally-restricted, selective cannabinoid receptor
type 1 (CB1) inverse agonist. Potential indications for CRB-4001
include NASH, among others. Corbus plans to start a Phase 1 study
of CRB-4001 in 2019, intended to be followed by a National
Institutes of Health (NIH)-funded proof-of-concept Phase 2
study.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
Statements in this press release that are not
statements of historical fact are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, without limitation,
statements about Corbus’ expectations regarding the completion,
timing and size of its public offering and the anticipated use of
proceeds therefrom. Words such as “believe,” “anticipate,” “plan,”
“expect,” “intend,” “may,” “goal,” “potential” and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements necessarily contain these
identifying words. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with market conditions as well as risks and uncertainties
associated with Corbus’ business and finances in general, including
the risks and uncertainties in the section captioned “Risk Factors”
in the prospectus supplement related to the public offering that
was filed with the SEC and the Company’s most recently filed Annual
Report on Form 10-K and subsequently filed Quarterly Reports on
Form 10-Q. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Corbus undertakes
no obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7745Email:
ir@corbuspharma.com
Lindsey Smith, Associate Director, Investor Relations and
Corporate CommunicationsPhone: +1 (617) 415-7749Email:
mediainfo@corbuspharma.com
Jenene ThomasJenene Thomas Communications, LLCPhone: +1 (833)
475-8247Email: crbp@jtcir.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024